|
|
|
Issue Open Date
|
24-Aug-26
|
|
|
|
Issue Closing Date
|
27-Aug-26
|
|
|
|
Application Money
|
100
|
|
|
|
Allotment Money
|
|
|
|
|
|
|
|
Price Band
|
938
-
988
|
|
|
|
Minimium Application No.
|
15
|
|
|
|
Issue Size (Shares)
|
18734736
|
|
|
|
Market Lot
|
1
|
|
|
|
|
|
|
Objective
|
|
1. Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company; and2. General corporate purposes.
|
|
|
|
|
|
|
Category
|
No. of Shares
|
No. of Shares
|
Subscription Ratio
|
|
|
Offered / Reserved |
Bid For |
|
|
Non-Institutional Investors
|
|
|
|
|
Qualified Institutional Buyers
|
|
|
|
|
Retail Individual Investors
|
|
|
|
|
|
|
|
Business Description:
We are a research and development-driven, science-based pharmaceutical and biotechnology company withcapabilities across three platforms- organic chemistry, biotechnology and complex injectables. We have a globalleadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients (“APIs”) in volumeterms in Fiscal 2025, with a global volume market share of 36.2% in corticosteroid and 44.2% in steroidal-hormoneAPIs. (Source: F&S Report) We are the only Indian and global company to have a presence across the top 10corticosteroid and steroidal-hormone APIs in Fiscal 2025, (Source: F&S Report) demonstrating the depth of ourportfolio. We manufacture these products using fermentation and multi-step complex chemical reactions. With over30 years of industry experience, we have evolved from a lab-scale steroidal-hormone API manufacturer in 1995 intoan industrial-scale, backward-integrated platform with approvals from the United States Food and DrugAdministration (“US FDA”), European Union Good Manufacturing Practices (“EU-GMP”), Ministry of Food andDrug Safety, Korea and other global organisations. We have leveraged our deep capabilities across organic chemistry,biotechnology, and complex injectables to operate as a contract development and manufacturing organisation(“CDMO”) variably for specialty pharmaceutical and nutraceutical companies globally, offering products andservices across the three platforms in which we also manufacture our own products. As of June 30, 2025, we had twooperational industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67metric tonnes (“MT”) and fermentation capacity of 300 kilolitres (“KL”). Further, as of the date of this Draft RedHerring Prospectus, we have newly commissioned two additional manufacturing facilities, leading to an aggregate maximum chemical synthesis capacity of 584.67 MT, maximum fermentation capacity of 700 KL, and complexinjectables capacity of 20 million vials per annum, enabling us to function as a vertically integrated ‘microbe-topharmacy’and ‘farm-to-pharmacy’ platform with cost-efficient operations. Our biotechnology facilities are equippedwith fermenters of 5 KL, 35 KL and 100 KL, providing us flexibility in the scale of our operations. Further, we are inthe process of expanding our biologics capacity by adding a proposed dedicated 14 KL (comprising two reactors of 7KL each) fermentation capacity for biologics manufacturing in Ujjain.
|
|
|
Promoter's Holding
|
|
|
|
Total Share Capital
|
21633968
|
|
|
|
Offered to Public
|
18734736
|
|
|
|
Promoter's Holding (Pre-Issue)
|
34.47
|
|
|
|
Promoter's Holding (Post-Issue)
|
|
|
|
|
|
|
|
|
|
|
|
|
Address |
385 / 2
Pigdamber
Near Mashal Hotel
Rau
Indore
,
Madhya Pradesh
,
453446
Phone :
0731-6676405
Email :
secretarial@symbiotec.com
Website :
www.symbiotec.com
|
|
|
|
Registrar |
MUFG Intime India Pvt Ltd.
C 101
247 Park
LBS Marg
Vikhroli (West)
Mumbai
|
|
|
|
Listed at |
|
BSE, NSE
|
|
|
|
Lead Manager |
Avendus Capital Pvt Ltd.
JM Financial Ltd.
Motilal Oswal Investment Advisors Pvt Ltd
Nomura Financial Advisory & Securities (India) Pvt Ltd.
|
|
|
|
Promoters |
Anil Satwani
Kashish Satwani
Satwani Holdings LLP
Sushil Satwani
|
|
